Quarterly report pursuant to Section 13 or 15(d)

CONCENTRATIONS

v3.5.0.2
CONCENTRATIONS
6 Months Ended
Jun. 30, 2016
Notes to Financial Statements  
Note 15 - CONCENTRATIONS

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

 

The Company's revenues earned from sale of products and services for the three months ended June 30, 2016 included 14%, 14%, 14% and 14% (aggregate of 56%) from four customers of the Company's total revenues.

 

The Company's revenues earned from sale of products and services for the six months ended June 30, 2016 included 11%, 15% and 10% (aggregate of 36%) from three customers of the Company's total revenues.

 

The Company's revenues earned from sale of products and services for the three months ended June 30, 2015 included 22%, 23% and 11% (aggregate of 56%) from three customers of the Company's total revenues.

 

The Company's revenues earned from sale of products and services for the six months ended June 30, 2015 included 16%, 27%, 10% and 13% (aggregate of 66%) from four customers of the Company's total revenues.

 

Four customers accounted for 10%, 42%, 18% and 13% (aggregate of 83%) of the Company's total accounts receivable at June 30, 2016 and two customers accounted for 49% and 20% of the Company's total accounts receivable at December 31, 2015.

 

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.